Modulating The K(ATP) Channel: The Potential Drug Target (P10744)

Target Name: K(ATP) Channel

NCBI ID: P10744

K(ATP) Channel

Other Name(s): K(ATP) Ch

Modulating The K(ATP) Channel: The Potential Drug Target

The K(ATP) channel is a family of transmembrane proteins that play a crucial role in intracellular signaling. The K(ATP) channel is composed of four subunits: K1, K2, K3, and K4. These subunits form a cation-exchange mechanism , allowing for the transfer of ATP energy across the membrane. The K(ATP) channel is a critical regulator of various cellular processes, including intracellular signaling, neurotransmission, and muscle contractions.

The K(ATP) channel has been identified as a potential drug target due to its involvement in various diseases, including heart failure, hypertension, and neurodegenerative signaling disorders. The channel is also involved in many normal physiological processes, such as muscle contractions and intracellular signaling . This makes it an attractive target for drug development due to its potential impact on a wide range of cellular processes.

One of the challenges in studying the K(ATP) channel is its complexity. The channel is composed of multiple subunits that interact with each other in complex ways to regulate its function. This makes it difficult to identify and understand the full effects of K( ATP) channel modulators.

In addition, the K(ATP) channel is a highly regulated system, and any changes in its function can have a significant impact on the cell. This makes it difficult to study the channel's effects on normal cellular processes, as well as its potential as a drug target.

Despite these challenges, research into the K(ATP) channel is ongoing, and several new compounds have been shown to modulate its function. These compounds can be used to study the channel's biology, as well as to develop new treatments for various diseases.

One of the most well-known compounds that has been shown to modulate the K(ATP) channel is Revlimid (1-[[4-(2-methylphenyl)-1H-pyrenyl]-4-carboxylic acid). Revlimid is a potent modulator of the K(ATP) channel that has been shown to increase the opening rate of the channel and enhance its function.

Revlimid works by binding to the channel's extracellular domain, where it can alter the activity of the K+ channels. This increase in the open rate of the channel allows for an increased influx of calcium ions, which can lead to increased muscle contractions and other cellular processes.

Another compound that has been shown to modulate the K(ATP) channel is NXY2 (1-[(1-naphthalen-2-yl)-1H-pyrenyl]-4-carboxylic acid). NXY2 is a potent inhibitor of the K( ATP) channel that has been shown to reduce the open rate of the channel and decrease its function.

NXY2 works by binding to the channel's intracellular domain, where it can alter the activity of the K+ channels. This reduction in the open rate of the channel allows for a decrease in the influx of calcium ions, which can lead to decreased muscle contractions and other cellular processes.

In conclusion, the K(ATP) channel is a complex system that is involved in many cellular processes. The channel is a potential drug target due to its involvement in various diseases, including heart failure, hypertension, and neurodegenerative disorders. Further research is needed to fully understand the channel's biology and develop new treatments for various diseases. Compounds such as Revlimid and NXY2 have the potential to modulate the channel's function and be used in drug development.

Protein Name: K(ATP) Channel (nonspecified Subtype)

The "K(ATP) Channel Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about K(ATP) Channel comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets